Fig. 1: Adherence to remote DHT monitoring. | npj Digital Medicine

Fig. 1: Adherence to remote DHT monitoring.

From: Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab

Fig. 1

Mean (error shading represents 95% confidence intervals) adherence to daily (a) active testing (AT) with the smartphone and (b) passive monitoring (PM) with the smartwatch and smartphone Roche PD Mobile Application v2 during Parts 1 (i.e., weeks 0–52 since randomization) and 2 (i.e., weeks 52–104 since randomization) of the PASADENA study.

Back to article page